Bioyitech to Showcase at Hangzhou New Nutrition Conference, Exploring the Future of Probiotics in Chronic Disease Management

The highly anticipated 2025 Hangzhou New Nutrition Conference is set to commence on June 5th. As an innovative enterprise in the field of Probiotics and health, Bioyitech will present its latest research and application achievements, participating in both thematic presentations and a roundtable forum to explore the forefront trends of probioticsin chronic disease prevention and industrial upgrading with industry experts.

The highly anticipated 2025 Hangzhou New Nutrition Conference is set to commence on June 5th. As an innovative enterprise in the field of probiotics and health, Bioyitech will present its latest research and application achievements, participating in both thematic presentations and a roundtable forum to explore the forefront trends of probioticsin chronic disease prevention and industrial upgrading with industry experts.

Keynote by Authority: Probiotics in Metabolic Disease Management

During the conference, Professor Zheng Chao, Director of the Department of Endocrinology at the Second Affiliated Hospital of Zhejiang University School of Medicine and doctoral supervisor, along with Li Jiadong, Co-founder and General Manager of Bioyitech, will deliver a keynote speech titled "Treating and Preventing Chronic Diseases: Probiotics in Metabolic Disease Management." Professor Zheng, a leading expert in endocrinology, will delve into the association between the gut microbiota and metabolic diseases (such as diabetes and obesity) based on clinical practice and the latest research, exploring the scientific value and application prospects of probiotics in disease intervention and health management.The main star strains involved are Bifidobacterium animalissubsp. lactis F1-7 andBifidobacterium animalis subsp. lactis BA-C9.

Roundtable Forum: Discussing the Future Transformation of the Probiotic Industry

At the "Future Transformation of the Probiotic Industry" roundtable forum, held concurrently with the conference, Li Jiadong, Co-founder and General Manager of Bioyitech, will engage in in-depth discussions with industry leaders, research experts, and representatives from the industrial chain. They will explore the upgrading paths and development opportunities of the probiotic industry from perspectives including technological innovation, market demand, and policy guidance. Bioyitech is committed to driving the industrialization of probiotics in the field of precision health through scientific research, and this sharing will inject new ideas into the industry.